Shares of Omnicell, Inc. (NASDAQ:OMCL) Marketed by Harel Insurance Investments & Financial Services Ltd.


Harel Insurance Investments & Financial Services Ltd.NASDAQ: OMCLGet Votes) and 15.4% in the first quarter, according to the company in its most recent statement with the Securities and Exchange Commission (SEC). The fund owned 885 shares of the company’s stock after selling 161 shares during the period. Harel Insurance Investments & Financial Services Ltd. holdings in Omnicell were worth $115,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its position in shares of Omnicell by 255.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 617,199 shares of the company’s stock valued at $111,367,000 after acquiring an additional 443,378 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in shares of Omnicell by 12.5% ​​in the first quarter. Conestoga Capital Advisors LLC now owns 1,691,338 shares of the company’s stock valued at $219,011,000 after acquiring an additional 188,112 shares in the last quarter. Great Lakes Advisors LLC bought a new stake in shares of Omnicell in the 4th quarter valued at about $13,636,000. Select Equity Group LP bought a new stake in shares of Omnicell in the fourth quarter worth about $8,875,000. Finally, Yousif Capital Management LLC purchased a new stake in shares of Omnicell in the 4th quarter valued at approximately $7,314,000.

Omnicell Trading Down 2.6%

NASDAQ: OMCL opened at $110.72 on Monday. Omnicell, Inc. it has a 1 year low of $104.32 and a 1 year high of $187.29. The company’s fifty-day moving average is $112.72 and its 200-day moving average is $126.26. The company has a market capitalization of $4.89 billion, a PE ratio of 74.31, a PEG ratio of 3.58 and a beta of 1.13.

Omnicell (NASDAQ: OMCLGet Votes) last posted their results on Thursday, April 28th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.13. Omnicell had a margin of 6.00% and a return of 11.35%. The business had revenue of $319.00 million for the quarter, compared to analyst estimates of $313.98 million. During the same period last year, the business posted $0.62 EPS. Omnicell’s revenue was up 26.7% compared to the same quarter last year. As a group, analysts expect that Omnicell, Inc. will post 2.81 EPS for the current year.

Changes in Analyst Ratings

OMCL has been the subject of several research reports. TheStreet lowered shares of Omnicell from a “b-” rating to a “c+” rating in a research report on Tuesday, May 17th. Piper Sandler cut their price target on shares of Omnicell from $181.00 to $162.00 in a research report on Monday, May 2nd. SVB Leerink initiated coverage on shares of Omnicell in a research report on Friday, July 15th. They issued a “market” rating and a $124.00 target price for the company. StockNews.com initiated coverage on shares of Omnicell in a research note on Thursday, March 31st. They put a “hold” rating on the stock. Finally, Wells Fargo & Company dropped their target price on shares of Omnicell from $188.00 to $158.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 3rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a “Moderate Buy” rating and a target price of $173.80.

Insider Activity at Omnicell

In other Omnicell news, EVP Scott Peter Seidelmann sold 3,765 shares of the company’s stock in a transaction on Thursday, June 16th. The shares were traded at an average price of $110.15, for a total value of $414,714.75. Following the sale, the vice president now owns 40,789 shares in the company, valued at approximately $4,492,908.35. The project was revealed in a document issued by the Securities & Exchange Commission, which is available through SEC website. 2.76% of the stock is currently owned by insiders.

About Omnicell

(Get Votes)

Omnicell, Inc., together with its subsidiaries, provides pharmaceutical solutions and equipment for use in healthcare systems and pharmaceuticals in the United States and around the world. The company provides automation solutions to improve clinical workflows in hospital-based patient care environments; XT Series medical equipment and products used in nursing units and other medical areas of the hospital, as well as special equipment for surgical equipment; The Omnicell Interface software that provides interface and integration between medical devices that use drugs or products, as well as information management systems for medical facilities; and robotics to help store and retrieve boxed medications.

read more

Want to see other hedge funds holding OMCL? Go to HoldingsChannel.com to access the latest 13F filings and insider trading for Omnicell, Inc.NASDAQ: OMCLGet Votes).



Receive Omnicell Daily News & Reviews – Enter your email address below to receive a concise daily summary of the latest news and expert opinions on Omnicell and related companies with MarketBeat.com ‘s FREE daily email newsletter.